Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors

Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors have?

Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors has 3,241 citations in the OpenAlex counts ScholarIQ stores.

When was Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors published?

Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors has 2017 year in the ScholarIQ index.

What is the open-access status of Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors?

Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors has bronze oa status in the ScholarIQ index.

What is the DOI of Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors?

The DOI for Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors is on the source record.

What is the PMID of Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors?

The PMID for Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors is on the source record.

What is the OpenAlex record for Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors?

The OpenAlex for Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors is on the source record.